Clinical Trials Logo

Clinical Trial Summary

Women were invited to attend colposcopy within two-four months after a positive screening test (two consecutive screening tests indicating low-grade squamous intraepithelial lesions (LSIL) and HPV positivity or a single screening test indicating high grade squamous intraepithelial lesions (HSIL)), according to national guidelines


Clinical Trial Description

To describe the source population, the overall number of invitations and tests taken in the region during the study period were retrieved from the Swedish National Cervical Screening Registry (NKCx), which has an almost 100% coverage of screening history in Sweden since 1993. Women were invited to attend colposcopy within two-four months after a positive screening test (two consecutive screening tests indicating low-grade squamous intraepithelial lesions (LSIL) and HPV positivity or a single screening test indicating high grade squamous intraepithelial lesions (HSIL)), according to national guidelines. All colposcopies were performed in 2018 and 2019 at the Department of Obstetrics and Gynecology, Falun Hospital, by a specialist in Obstetrics and Gynecology. Digital imaging ensured the possibility of subsequent re-review by an expert colposcopist at the Karolinska University Hospital. The colposcopies consisted of a microscopic evaluation of the uterine cervix including punch biopsies as well as endocervical sampling with liquid based cytology (LBC). In the absence of visible colposcopic lesions, random biopsies at 6 and 12 o´clock were taken to ensure histopathological confirmation in all women. Women with colposcopic and/or histopathologic findings that required treatment underwent excision (conization) according to national guidelines. The consultation also included questions on medical history according to a protocol designed for the study. Analysis of histopathology and cytology was performed at the Department of Pathology, Falun Hospital. An LBC sample was analyzed for the presence of 14 high risk HPV (hrHPV) genotypes and cytology. HPV samples were tested at the Department of Laboratory Medicine, Falun Hospital, using amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization (Cobas 4800, Roche Molecular Systems). LBC samples positive for high risk types other than HPV 16/18, were sent for further genotyping to the Center for Cervical Cancer Prevention at the Karolinska University Laboratory Huddinge. Information on vaccination status was retrieved through linkage to the National HPV Vaccination Register (SVEVAC), an informed consent-based register in operation since the introduction of HPV vaccination In Sweden, and data was further complemented by linkage to the Prescribed Drug Register (PDR), a mandatory register on dispensed prescriptions in Sweden in operation since July 2005. All women were asked about their vaccination status after the colposcopic examination had been performed, and linkage to SVEVAC and PDR was run after all study colposcopies and laboratory analysis had been completed. Hence, vaccination status was blinded to the colposcopists, pathologists, and laboratory staff. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04909814
Study type Observational [Patient Registry]
Source Falu Hospital
Contact
Status Completed
Phase
Start date March 14, 2018
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A